查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957515

2026年全球非病毒基因遞送技術市場報告

Non-Viral Gene Delivery Technologies Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，非病毒基因轉殖技術的市場規模迅速擴張。預計該市場規模將從2025年的45.7億美元成長到2026年的52.8億美元，複合年成長率（CAGR）為15.5%。過去幾年成長要素包括：對病毒載體遞送方法的依賴、非病毒轉染試劑獲取困難、基因治療研究日益成長的興趣、質體DNA和mRNA遞送試劑盒使用量的增加，以及電穿孔和物理遞送技術的應用。

預計未來幾年非病毒基因遞送技術市場將快速成長，到2030年將達到92.6億美元，複合年成長率（CAGR）為15.1%。預測期內的成長要素包括：先進脂質和聚合物奈米顆粒的開發、預配方奈米顆粒技術的擴展、對基因編輯和RNA干擾（RNAi）療法的投資增加、對個人化基因治療解決方案的需求不斷成長，以及高通量和自動化遞送平台的整合。預測期內的關鍵趨勢包括：基於脂質和聚合物的非病毒遞送系統應用日益廣泛、CRISPR和Cas9基因編輯應用成長、對RNAi和DNA疫苗遞送平台的需求增加、體外和體內基因治療研究的擴展，以及細胞特異性和靶向性基因遞送試劑的開發。

個人化醫療需求的不斷成長預計將加速非病毒基因遞送技術市場的發展。個人化醫療是一種根據個人的基因特徵、生活方式和環境來最佳化預防、診斷和治療的醫療模式。這種需求的成長源自於基因組分析技術的進步，該技術能夠為每位患者提供精準診斷、個人化治療和最佳治療效果。隨著人們對個人化醫療的興趣日益濃厚，非病毒基因遞送技術也越來越受到關注，因為它可以安全靈活地導入患者特異性治療基因，同時避免病毒載體帶來的風險。例如，根據美國非營利組織「個人化醫療聯盟」（Coalition for Personalized Medicine）於2024年2月發布的報告，美國食品藥物管理局（FDA）在2023年核准了16種針對罕見疾病的新型個人化治療方法，高於2022年的6種。因此，個人化醫療需求的不斷成長正在推動非病毒基因遞送技術市場的發展。

非病毒基因遞送市場的主要企業正在推進非病毒基因治療平台等最尖端科技，以提高基因治療的安全性和療效。非病毒基因治療平台無需使用病毒即可將治療性基因和核酸導入細胞，從而實現針對多種疾病的精準可控遞送，並最大限度地降低免疫反應和風險。例如，2023年10月，專注於基因治療的美國生物技術公司Generation Bio宣布推出免疫抑制性DNA（iqDNA）。這種改良版的封閉式DNA（ceDNA）採用脂質奈米顆粒（LNP）進行遞送，在小鼠和非人靈長類動物中產生的細胞激素譜和抗性與修飾的mRNA相似，從而逃避免疫系統的辨識。由於耐受性更佳，Generation Bio已將iqDNA作為其所有項目（包括其旗艦A型血友病A治療項目）的核心DNA有效載荷。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球非病毒基因遞送技術市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 清單：主要原料、資源和供應商
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章：全球市場趨勢與策略

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 數位化、雲端運算、巨量資料、網路安全
    • 工業4.0和智慧製造
    • 人工智慧（AI）和自主人工智慧
    • 物聯網、智慧基礎設施、互聯生態系統
  • 主要趨勢
    • 基於脂質和聚合物的非病毒遞送系統的擴展
    • CRISPR和Cas9基因編輯技術的應用範圍不斷擴大。
    • 對RNAi和DNA疫苗遞送平台的需求不斷成長
    • 擴大體外和體外基因治療的研究
    • 細胞特異性和定向基因遞送試劑的開發

第5章 終端用戶產業市場分析

  • 生技公司
  • 生物製藥公司
  • 研究機構
  • 大學和研究機構
  • 受託研究機構（CRO）

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球非病毒基因遞送技術市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球非病毒基因遞送技術市場規模、比較及成長率分析
  • 全球非病毒基因遞送技術市場表現：規模與成長，2020-2025年
  • 全球非病毒基因遞送技術市場預測：規模與成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

  • 依產品
  • 試劑和試劑盒、輸送裝置和預配製奈米顆粒。
  • 送貨
  • 體外、體內、離體
  • 透過技術
  • 電穿孔、脂質體轉染、聚合物轉染、物理方法（顯微注射、基因槍）、奈米顆粒
  • 透過使用
  • 基因療法、去氧核糖核酸(DNA) 疫苗、核糖核酸干擾 (RNAi)、成簇規律間隔短叢集重複序列 (CRISPR) 或 Cas9 基因編輯、蛋白質表達
  • 按最終用途
  • 生物技術和生物製藥公司、研究機構和學術機構以及其他最終用戶
  • 按類型細分：試劑和試劑盒
  • 轉染試劑、質體去氧核糖核酸（DNA）試劑盒、信使核糖核酸（RNA）遞送試劑盒、小干擾核糖核酸（RNA）遞送試劑盒、成簇規律間隔短叢集重複序列相關蛋白（CRISPR）試劑、細胞特異性遞送試劑
  • 按類型細分：輸送裝置
  • 電穿孔系統、顯微注射系統、基因槍或生物標靶遞送裝置、超音波遞送裝置、動態基因遞送系統
  • 按類型細分：預製奈米顆粒
  • 脂質奈米顆粒、聚合物奈米顆粒、金奈米顆粒、樹狀聚合物聚合物奈米顆粒、奈米碳管顆粒、無機化合物奈米顆粒

第10章 區域與國別分析

  • 全球非病毒基因遞送技術市場：按地區分類，實際結果與預測，2020-2025年、2025-2030年預測、2035年預測
  • 全球非病毒基因遞送技術市場：按國家/地區分類，實際結果和預測，2020-2025年、2025-2030年預測、2035年預測

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 非病毒基因遞送技術市場：競爭格局及市場佔有率（2024年）
  • 非病毒基因遞送技術市場：公司評估矩陣
  • 非病毒基因遞送技術市場：公司概況
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Evonik Industries AG
    • Moderna Inc.

第37章 其他大型企業和創新企業

  • Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

第38章：全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年非病毒基因遞送科技市場：提供新機會的國家
  • 2030年非病毒基因遞送技術市場：充滿新機會的細分領域
  • 2030年非病毒基因遞送技術市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第41章附錄

簡介目錄
Product Code: PH4MNVGD01_G26Q1

Non-viral gene delivery technologies are methods for transferring genetic material into cells without using viruses as carriers. These technologies reduce safety risks and immune responses associated with viral vectors while enabling precise and controlled gene delivery. Their primary purpose is to modify or regulate gene expression for applications such as treating genetic diseases and advancing cell-based therapies.

The main product types of non-viral gene delivery technologies include reagents and kits, delivery devices, and pre-formulated nanoparticles. Reagents and kits are ready-to-use chemical formulations designed to introduce genetic material into cells without viral involvement. Delivery can occur through various modes, including in vitro, in vivo, and ex vivo, using technologies such as electroporation, lipid-based transfection, polymer-based transfection, physical methods (microinjection and gene gun), and nanoparticle-mediated delivery. These technologies are applied in multiple areas, including gene therapy, DNA vaccines, RNA interference (RNAi), CRISPR/Cas9 gene editing, and protein expression. Key end users include biotechnology and biopharmaceutical companies, research and academic institutes, and other organizations involved in genetic research and therapeutics.

Tariffs have impacted the non-viral gene delivery technologies market by increasing the cost of imported reagents, nanoparticles, and delivery devices, affecting both research and clinical applications. Segments like pre-formulated nanoparticles and advanced delivery devices are most affected, particularly in North America and Europe where imports constitute a significant share. While tariffs have raised operational costs and slowed adoption, they have also encouraged domestic manufacturing, investment in local R&D, and innovation in cost-effective gene delivery technologies.

The non-viral gene delivery technologies market research report is one of a series of new reports from The Business Research Company that provides non-viral gene delivery technologies market statistics, including non-viral gene delivery technologies industry global market size, regional shares, competitors with a non-viral gene delivery technologies market share, detailed non-viral gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral gene delivery technologies industry. This non-viral gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-viral gene delivery technologies market size has grown rapidly in recent years. It will grow from $4.57 billion in 2025 to $5.28 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to reliance on viral delivery methods, limited availability of non-viral transfection reagents, growing interest in gene therapy research, increasing use of plasmid dna and mrna delivery kits, adoption of electroporation and physical delivery techniques.

The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $9.26 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to development of advanced lipid and polymer nanoparticles, expansion of pre-formulated nanoparticle technologies, rising investment in gene editing and rnai therapeutics, increasing demand for personalized gene therapy solutions, integration of high-throughput and automated delivery platforms. Major trends in the forecast period include increasing adoption of lipid-based and polymer-based non-viral delivery systems, growth in crispr and cas9 gene editing applications, rising demand for rnai and dna vaccine delivery platforms, expansion of ex-vivo and in-vivo gene therapy research, development of cell-specific and targeted gene delivery reagents.

The surging need for personalized medicine is set to accelerate the non-viral gene delivery technologies market ahead. Personalized medicine tailors prevention, diagnosis, and therapy to an individual's distinct genetics, habits, and surroundings. This rising demand arises from progress in genomic sequencing, enabling precise diagnostics, customized treatments, and superior results suited to each patient. The heightened emphasis on personalized medicine spurs interest in non-viral gene delivery technologies, which provide secure, flexible ways to insert patient-specific therapeutic genes, avoiding viral vector hazards. For example, in February 2024, the Personalized Medicine Coalition, a US non-profit, noted that the FDA greenlit 16 new personalized therapies for rare diseases in 2023, up from 6 in 2022. Hence, the escalating demand for personalized medicine is propelling the non-viral gene delivery technologies market.

Key players in the non-viral gene delivery market are advancing cutting-edge options like non-viral genetic medicine platforms to enhance gene therapy safety and performance. A non-viral genetic medicine platform introduces therapeutic genes or nucleic acids into cells sans viruses, minimizing immune responses and risks, while allowing accurate, regulated delivery for diverse conditions. For instance, in October 2023, Generation Bio Co., a US biotech firm focused on genetic medicines, unveiled immune-quiet DNA (iqDNA). This enhanced version of their closed-ended DNA (ceDNA) dodges innate immune sensing, displaying cytokine profiles and tolerance akin to modified mRNA in mice and non-human primates via lipid nanoparticle (LNP) delivery. Thanks to iqDNA's enhanced tolerability, Generation Bio is adopting it as the core DNA payload across its programs, including the flagship hemophilia A initiative.

In September 2023, SOHM Inc., a US pharmaceutical company expert in generic and private-label drug production and distribution, purchased ABBIE Inc. for an undisclosed sum. This move bolsters SOHM's expertise in non-viral gene delivery technologies, equipping it to pioneer gene-editing innovations and grow its footprint in the expanding genetic therapeutics arena. ABBIE Inc. is a US-based gene-editing platform that transports genetic payloads through non-viral vectors.

Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

North America was the largest region in the non-viral gene delivery technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-viral gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral gene delivery technologies market consists of revenues earned by entities by providing services such as genetic material formulation, delivery system development, and transfection optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-viral gene delivery technologies market also includes sales of lipid nanoparticles, polymer-based carriers, electroporation devices, and microinjection systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Gene Delivery Technologies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses non-viral gene delivery technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral gene delivery technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral gene delivery technologies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product: Reagents And Kits; Delivery Devices; Pre-Formulated Nanoparticles
  • 2) By Delivery: In-Vitro; In-Vivo; Ex-Vivo
  • 3) By Technology: Electroporation; Lipid-Based Transfection; Polymer-Based Transfection; Physical Methods (Microinjection, Gene Gun); Nanoparticles
  • 4) By Application: Gene Therapy; Deoxyribonucleic Acid (DNA) Vaccines; Ribonucleic Acid Interference (RNAi); Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing; Protein Expression
  • 5) By End-Use: Biotechnology And Biopharmaceutical Companies; Research And Academic Institutes; Other End-Uses
  • Subsegments:
  • 1) By Reagents And Kits: Transfection Reagents; Plasmid Deoxyribonucleic Acid (DNA) Kits; Messenger Ribonucleic Acid (RNA) Delivery Kits; Small Interfering Ribonucleic Acid (RNA) Delivery Kits; Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents; Cell-Specific Delivery Reagents
  • 2) By Delivery Devices: Electroporation Systems; Microinjection Systems; Gene Guns Or Biolistic Delivery Devices; Ultrasound-Mediated Delivery Devices; Hydrodynamic Gene Delivery Systems
  • 3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles; Polymer-Based Nanoparticles; Gold-Based Nanoparticles; Dendrimer-Based Nanoparticles; Carbon Nanotube-Based Nanoparticles; Inorganic Compound-Based Nanoparticles
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; Evonik Industries AG; Moderna Inc.; Lonza Group AG; Bio-Rad Laboratories Inc.; Takara Bio Inc.; GenScript Biotech Corporation; ReCode Therapeutics Inc.; Altogen Biosystems Inc.; Generation Bio; Indee Labs Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Non-Viral Gene Delivery Technologies Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Non-Viral Gene Delivery Technologies Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Non-Viral Gene Delivery Technologies Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Non-Viral Gene Delivery Technologies Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Lipid-Based And Polymer-Based Non-Viral Delivery Systems
    • 4.2.2 Growth In Crispr And Cas9 Gene Editing Applications
    • 4.2.3 Rising Demand For Rnai And Dna Vaccine Delivery Platforms
    • 4.2.4 Expansion Of Ex-Vivo And In-Vivo Gene Therapy Research
    • 4.2.5 Development Of Cell-Specific And Targeted Gene Delivery Reagents

5. Non-Viral Gene Delivery Technologies Market Analysis Of End Use Industries

  • 5.1 Biotechnology Companies
  • 5.2 Biopharmaceutical Companies
  • 5.3 Research Institutes
  • 5.4 Academic And University Laboratories
  • 5.5 Contract Research Organizations (Cros)

6. Non-Viral Gene Delivery Technologies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Non-Viral Gene Delivery Technologies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Non-Viral Gene Delivery Technologies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Non-Viral Gene Delivery Technologies Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Non-Viral Gene Delivery Technologies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Non-Viral Gene Delivery Technologies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Non-Viral Gene Delivery Technologies Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Non-Viral Gene Delivery Technologies Market Segmentation

  • 9.1. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles
  • 9.2. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • In-Vitro, In-Vivo, Ex-Vivo
  • 9.3. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles
  • 9.4. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression
  • 9.5. Global Non-Viral Gene Delivery Technologies Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses
  • 9.6. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Reagents And Kits, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents
  • 9.7. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Delivery Devices, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems
  • 9.8. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Pre-Formulated Nanoparticles, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles

10. Non-Viral Gene Delivery Technologies Market Regional And Country Analysis

  • 10.1. Global Non-Viral Gene Delivery Technologies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Non-Viral Gene Delivery Technologies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Non-Viral Gene Delivery Technologies Market

  • 11.1. Asia-Pacific Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Non-Viral Gene Delivery Technologies Market

  • 12.1. China Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Non-Viral Gene Delivery Technologies Market

  • 13.1. India Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Non-Viral Gene Delivery Technologies Market

  • 14.1. Japan Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Non-Viral Gene Delivery Technologies Market

  • 15.1. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Non-Viral Gene Delivery Technologies Market

  • 16.1. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Non-Viral Gene Delivery Technologies Market

  • 17.1. South Korea Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Non-Viral Gene Delivery Technologies Market

  • 18.1. Taiwan Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Non-Viral Gene Delivery Technologies Market

  • 19.1. South East Asia Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Non-Viral Gene Delivery Technologies Market

  • 20.1. Western Europe Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Non-Viral Gene Delivery Technologies Market

  • 21.1. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Non-Viral Gene Delivery Technologies Market

  • 22.1. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Non-Viral Gene Delivery Technologies Market

  • 23.1. France Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Non-Viral Gene Delivery Technologies Market

  • 24.1. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Non-Viral Gene Delivery Technologies Market

  • 25.1. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Non-Viral Gene Delivery Technologies Market

  • 26.1. Eastern Europe Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Non-Viral Gene Delivery Technologies Market

  • 27.1. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Non-Viral Gene Delivery Technologies Market

  • 28.1. North America Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Non-Viral Gene Delivery Technologies Market

  • 29.1. USA Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Non-Viral Gene Delivery Technologies Market

  • 30.1. Canada Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Non-Viral Gene Delivery Technologies Market

  • 31.1. South America Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Non-Viral Gene Delivery Technologies Market

  • 32.1. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Non-Viral Gene Delivery Technologies Market

  • 33.1. Middle East Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Non-Viral Gene Delivery Technologies Market

  • 34.1. Africa Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Non-Viral Gene Delivery Technologies Market Regulatory and Investment Landscape

36. Non-Viral Gene Delivery Technologies Market Competitive Landscape And Company Profiles

  • 36.1. Non-Viral Gene Delivery Technologies Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Non-Viral Gene Delivery Technologies Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Non-Viral Gene Delivery Technologies Market Company Profiles
    • 36.3.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Non-Viral Gene Delivery Technologies Market Other Major And Innovative Companies

  • Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

38. Global Non-Viral Gene Delivery Technologies Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Non-Viral Gene Delivery Technologies Market

40. Non-Viral Gene Delivery Technologies Market High Potential Countries, Segments and Strategies

  • 40.1 Non-Viral Gene Delivery Technologies Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Non-Viral Gene Delivery Technologies Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Non-Viral Gene Delivery Technologies Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer